John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)
November 8, 2021 08:31 AM ESTUpdated 08:43 AM
Bioregnum
Cell/Gene Tx

John Maraganore steps in­to a new role at an up­start biotech as the god­fa­ther phase of his ca­reer takes shape

John Maraganore isn’t wast­ing any time shift­ing to a new post-Al­ny­lam phase in his long biotech ca­reer. Start­up wun­derkind Beam Ther­a­peu­tics has lured the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

Evotec gains on Halozyme's takeover pro­pos­al

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times